172 related articles for article (PubMed ID: 1597662)
21. Lymphokine-activated killer (LAK) cells. V. 8-Mercaptoguanosine as an IL-2-sparing agent in LAK generation.
Thompson RA; Ballas ZK
J Immunol; 1990 Nov; 145(10):3524-31. PubMed ID: 1700014
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
Lin TH; Chu TM
Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
[TBL] [Abstract][Full Text] [Related]
23. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
24. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
25. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
Horton SA; Oldham RK; Yannelli JR
Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
[TBL] [Abstract][Full Text] [Related]
26. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
27. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
Atzpodien J; Gulati SC
Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
[TBL] [Abstract][Full Text] [Related]
28. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
[TBL] [Abstract][Full Text] [Related]
29. Human spleen and peripheral blood lymphocytes activated by interleukin-2 have similar phenotypic and functional characteristics.
Voltarelli JC; Rayner AA; Garovoy MR; Stites DP
J Biol Response Mod; 1990 Feb; 9(1):103-7. PubMed ID: 2319257
[TBL] [Abstract][Full Text] [Related]
30. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
31. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
32. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
33. The effects of staphylococcal protein A on human lymphokine-activated killer cell induction.
Lindemann RA; Singh KP; Shau H; Gupta RK
Cancer Immunol Immunother; 1991; 33(2):97-102. PubMed ID: 1709823
[TBL] [Abstract][Full Text] [Related]
34. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
35. [Experimental expansion and antitumor effects of LAK cells from cancer patient's peripheral blood].
Zhang BX
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):253-6. PubMed ID: 1396072
[TBL] [Abstract][Full Text] [Related]
36. Isolation of human NK cells and generation of LAK activity.
Whiteside TL
Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
[TBL] [Abstract][Full Text] [Related]
37. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
[TBL] [Abstract][Full Text] [Related]
38. Generation of LAK cells in vitro in patients with acute leukemia.
Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.
Schadendorf D; Böhm M; Möller P; Grünewald T; Czarnetzki BM
J Invest Dermatol; 1994 Jun; 102(6):838-42. PubMed ID: 8006445
[TBL] [Abstract][Full Text] [Related]
40. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin.
Berezhnaya NM; Vinnichuk YD; Belova OB
Exp Oncol; 2008 Mar; 30(1):52-5. PubMed ID: 18438341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]